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ABSTRACT
Background HER2 is a therapeutic target for metastatic 
colorectal cancer (mCRC), as demonstrated in the 
pivotal HERACLES- A (HER2 Amplification for Colo- rectaL 
cancer Enhanced Stratification) trial with trastuzumab 
and lapatinib. The aim of HERACLES- B trial is to assess 
the efficacy of the combination of pertuzumab and 
trastuzumab- emtansine (T- DM1) in this setting.
Methods HERACLES- B was a single- arm, phase II trial, in 
patients with histologically confirmed RAS/BRAF wild- type 
and HER2+ mCRC refractory to standard treatments. HER2 
positivity was assessed by immunohistochemistry and in 
situ hybridisation according to HERACLES criteria. Patients 
were treated with pertuzumab (840 mg intravenous 
load followed by 420 mg intravenous every 3 weeks) 
and T- DM1 (3.6 mg/kg every 3 weeks) until disease 
progression or toxicity. Primary and secondary end points 
were objective response rate (ORR) and progression- free 
survival (PFS). With a Fleming/Hern design (H0=ORR 10%; 
α=0.05; power=0.85), 7/30 responses were required to 
demonstrate an ORR ≥30% (H1).
Results Thirty- one patients, 48% with ≥4 lines of 
previous therapies, were treated and evaluable. ORR was 
9.7% (95% CI: 0 to 28) and stable disease (SD) 67.7% 
(95% CI: 50 to 85). OR/SD ≥4 months was associated 
with higher HER2 immunohistochemistry score (3+ vs 
2+) (p = 0.03). Median PFS was 4.1 months (95% CI: 3.6 
to 5.9). Drug- related grade (G) 3 adverse events were 
observed in two patients (thrombocytopaenia); G≤2 AE in 
84% of cycles (n = 296), mainly nausea and fatigue.
Conclusions HERACLES- B trial did not reach its primary 
end point of ORR; however, based on high disease 
control, PFS similar to other anti- HER2 regimens, and low 
toxicity, pertuzumab in combination with T- DM1 can be 
considered for HER2+mCRC as a potential therapeutic 
resource.
Trial registration number 2012-002128-33 and 
NCT03225937.
INTRODUCTION
Precision medicine in solid tumours was 
essentially born with the game changing 
discovery that the gene encoding HER2, the 
human epidermal growth factor receptor 2 
(ERBB2 formerly known as HER2/neu), was 
amplified and overexpressed in approxi-
mately 20% of patients with newly diagnosed 
breast cancers.1 Thereafter, deregulated 
HER2 became the target of several approved 
cancer drugs and anti- HER2 treatments 
turned out to be a phenomenal success story 
in breast cancer.2 Tumour- driving ERBB2 
Key questions
What is already known about this subject?
 ► HER2 is a therapeutic target for metastatic colorec-
tal cancer (mCRC), as demonstrated in the pivotal 
HERACLES- A trial with trastuzumab and lapatinib.
What does this study add?
 ► The HERACLES- B trial assessed the efficacy of a 
HER2- targeted combination of pertuzumab and 
trastuzumab- emtansine (T- DM1) in chemorefractory 
mCRC, showing a 9.7% overall response rate that 
was below the threshold selected as end point for 
success of the study.
 ► At the same time, it has been observed a high dis-
ease control (77.4%), and a PFS of 4.1 months that 
is similar to other anti- HER2 regimens.
How might this impact on clinical practice?
 ► The combination of pertuzumab and T- DM1 does not 
appear to induce meaningful tumour shrinkage as 
compared with other HER2- targeted options; how-
ever, based on high disease control, PFS and low 
toxicity, it can be considered for HER2+ mCRC as a 
potential alternative therapeutic resource.
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alterations have next been confirmed in many tumours 
types, including gastric, biliary, lung, ovary, and also in 
approximately 5% of colorectal cancer (CRCs).3–5 Our 
group tested several combinations of anti- HER2 drugs in 
randomised preclinical trials of patient- derived HER2+ 
CRC xenografts (HER2- PDXs), and elected to test first 
in the clinic a vertical HER2 blockade regimen consisting 
of trastuzumab combined with lapatinib, a dual HER1/
HER2 tyrosine kinase inhibitor6 in our first trial, named 
HERACLES- A, in which patients selection was performed 
by stringent CRC- specific HER2+ pathology criteria.4 7 
Results in the first 27 KRAS exon 2 wild- type patients show-
cased a 30% ORR, including two complete responses, 
one still without evidence of disease after 7 years, and an 
excellent median survival (10 months) considering the 
heavily pretreated population7 8
Leveraging liquid biopsies and rapid postmortem 
autopsy, we uncovered mechanisms of resistance to 
therapeutic HER2 blockade and suggested how to opti-
mise patient’s selection. First, we showed that plasma 
and tissue ERBB2 copy number positively correlates, the 
former distributing with a cut- off value highly predictive 
for clinical response.9 We then reported that resistance 
to anti- HER2 therapy is associated with KRAS mutations, 
BRAF amplification and other molecular alterations 
already known to sustain resistance in breast cancer.10
Results of HERACLES- A trial led to the inclusion of 
trastuzumab and lapatinib regimen in the 2019 NCCN 
Guidelines for mCRC and triggered clinical research to 
optimise of anti- HER2 regimens in this setting.11 12 To 
this aim, based on the encouraging efficacy in breast 
cancer,13 14 we studied in preclinical models of PDX a 
‘targeted chemotherapy’ precision approach combining 
the HER2/HER3 dimerisation inhibitor pertuzumab15 
with trastuzumab emtansine (T- DM1), and subsequently 
designed the HERACLES- B trial, evaluating this combina-
tion of drugs in patients with HER2+ mCRC.
METHODS
Preclinical colorectal cancer xenograft
Tumour implantation and expansion were performed as 
previously described.16 After engraftment in NOD- SCID 
(Nonobese diabetic- severe combined immunodeficiency) 
mice, established tumours (average volume 400 mm3) 
were treated with either single- agent or combination of 
pertuzumab (Roche Genentech) 20 mg/kg intraperito-
neal, once weekly; T- DM1 (Roche Genentech), 10 mg/
kg intravenous, once weekly and lapatinib (Carbosynth) 
100 mg/kg by oral gavage, daily. Tumour size was eval-
uated once weekly by calliper measurements and the 
approximate volume of the mass was calculated using the 
formula 4/3π·(d/2)2·D/2, where d is the minor tumour 
axis and D is the major tumour axis.
Study design and patients
HERACLES- B is a multicentre, open- label, phase II trial 
done at five academic centres in Italy (online supplemental 
appendix 1). Eligible patients were 18 years or older and 
had a histologically confirmed diagnosis of mCRC with 
RAS (KRAS exons 2, 3, 4; NRAS exons 2, 3, 4) wild- type 
status and HER2 positivity as defined by the CRC- specific 
HERACLES diagnostic criteria.4 Participants must had at 
least one measurable lesion, as defined by the Response 
Criteria Evaluation in Solid Tumours (RECIST) V.1.1; 
an Eastern Cooperative Oncology Group performance 
status score of 0 or 1 and adequate haematological, renal 
and hepatobiliary functions. Another major inclusion 
criterion was progression while on treatment or within 
6 months from treatment with approved standard drugs 
Figure 1 Efficacy in preclinical trials of pertuzumab and T- DM1 in patient- derived HER2+ CRC xenografts (HER2- PDXs). 
Tumour growth curves in tumour graft cohorts from individual patients with ERBB2 amplification treated with placebo or 
indicated HER2- targeted treatments (n=6 mice per group), showing long- lasting growth inhibition achieved with pertuzumab 
and T- DM1. TDM1: 10 mg/kg once weekly; pertuzumab: 20 mg/kg once weekly; lapatinib: 100 mg/kg/day.
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for mCRC (fluoropyrimidines, oxaliplatin, irinotecan, 
containing regimens, with or without anti- angiogenic or 
anti- EGFR antibodies).
Procedures
Patients enrolled received pertuzumab 840 mg intrave-
nous loading dose on the first day (D1) of cycle 1, followed 
by 420 mg intravenous on D1 of each subsequent three 
weekly cycle and T- DM1 3.6 mg/kg intravenous on D1 of 
each 3 weeks cycle. Treatment was continued until disease 
progression, occurrence of an adverse event requiring 
treatment cessation, withdrawal of consent or investigator 
decision to terminate treatment. Tumour assessments 
were evaluated at each centre in accordance with RECIST 
V.1.1 at baseline, at 6 weeks and every 9 weeks thereafter 
until progression. All tumour assessments were reviewed 
centrally by two radiologists (DR, AV) masked to outcomes 
using mintLesion V.3.1 software to collect, store and guide 
the revision of the imaging results. The imaging review 
protocol and tumour assessment reconciliation report 
are included in online supplemental appendix 2. Toxici-
ties and safety were assessed on the basis of the Common 
Terminology Criteria for Adverse Events (CTCAE) V.4.0. 
Figure 2 Consolidated Standards of Reporting Trials diagram of HERACLES- B trial. Between August 2012 and March 2018, 
1536 patients with KRAS exon 2 and BRAF wild type (WT) (from 15 March 2016 exons 2, 3, 4 KRAS and NRAS and BRAF WT) 
were screened by immunohistochemistry (IHC) and in situ hybridisation (ISH) as per HERACLES criteria. Ninety patients (5.9%) 
had a HER2+ tumour. HERACLES cohort A comprised overall 35 patients (27 original cohort plus 8 expansion cohort), of 
whom 32 were evaluable for response.8 Enrolment in cohort B (HERACLES B trial) started in August 2016, data were collected 
until March 2019 and final analysis and centralised radiological revision were completed by 30 July 2019. One patient signed 
consent but developed rapid disease progression and was locally indicated as not evaluable for efficacy. The patients was 
duly substituted as per protocol. However, the centralised revision of the treatment history subsequently revealed instead that 
patient was fully evaluable for both safety and efficacy as for protocol since two full cycles of treatment were delivered. For 
this reason, all analyses have been performed on 31 rather than 30 patients as originally intended. *From 15 March 2016 RAS 
WT (KRAS, NRAS exon 2, 3, 4).
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No dose reduction was allowed for pertuzumab, while 
T- DM1 was permitted to be reduced to 2.4 mg/kg intra-
venous per cycle; patients who needed further dose 
reductions were withdrawn from the study. Patients were 
screened for HER2 positivity at participating institutions 
on the most recently available formalin- fixed paraffin- 
embedded (FFPE) tumour sample and confirmed at the 
central pathology laboratory at Niguarda Cancer Center 
(Milan, Italy) as previously described.4 Next- generation 
sequencing (NGS)- based molecular analyses (Founda-
tion Medicine—Roche) of tumour tissue were performed 
on available FFPE specimens.
Outcomes
The primary objective was to define the antitumour 
activity of pertuzumab plus T- DM1 in patients with 
chemorefractory HER2+ mCRC. The primary end point 
was ORR and secondary end points were progression- free 
survival (PFS) and safety. Translational exploratory end 
points investigated association of tumour biomarkers and 
tumour response/resistance.
Statistical analysis
The sample size was determined according to the Fleming 
and Hern single stage design. For the primary objec-
tive, 30 patients were needed with a power of 85% and 
a one- sided α of 0.05, to test the null hypothesis that the 
proportion of patients achieving an objective response to 
the pertuzumab plus T- DM1 combination would be ≤10% 
versus the alternative hypothesis that the proportion of 
patients achieving an objective response would be 30% or 
more. Under these conditions, seven objective responses 
were needed to declare the study positive. Response was 
assessed in the intention- to- treat population. Time- to- 
event variables were estimated with the Kaplan- Meier 
product- limit method and p values for differences 
between curves were calculated with the log- rank test. We 
considered p values of 0.05 or less to show significance; 
Fisher’s exact test was used for subgroup comparisons of 
categorical variables. Analyses were conducted with SAS 
V.9.2 and Stata V.12.
RESULTS
Preclinical evaluation in HER2+ CRC PDXs of the combi-
nation of pertuzumab and T- DM1 demonstrated inhi-
bition of tumour growth and, interestingly, this activity 
was long- lasting, as it was maintained for several weeks 
after treatment discontinuation (figure 1). These results 
prompted us to launch the HERACLES- B trial as part of 
the HERACLES initiative and following HERACLES- A 
cohort. Between August 2012 and March 2018, 1536 
patients with KRAS exon 2 and BRAF wild type (from 
15 March 2016 exons 2, 3 and 4 KRAS, exons 2, 3 and 
4 NRAS and exon 15 BRAF wild type) were screened by 
immunohistochemistry (IHC) and in situ hybridisation 
(ISH)4 within the HERACLES programme. Enrolment 
in cohort B (HERACLES B trial) started in August 2016, 
data were collected until March 2019 and final analysis 
and centralised radiological revision were completed by 
30 July 2019. The Consolidated Standards of Reporting 
Trials flow diagram is reported in figure 2.
The majority of IHC HER2 diagnostic samples (80%) in 
eligible patients scored 3+ for HER2 at IHC. Fluorescence 
in situ hybridisation was performed in all the specimens 
confirming gene amplification. NGS in available FFPE 
specimens was also performed in 20/30 (67%) patients 
and confirmed ERBB2 amplification and RAS wild- type 
status in all samples. Most patients had colon tumour 
location, metastatic disease in multiple sites and almost 
half (48%) had been treated with at least four lines of 
chemotherapy including bevacizumab, aflibercept or 
regorafenib (table 1). Twenty- six patients (83%) had 
previously received therapy with an anti- EGFR antibody. 




Age in years 60 (50.5–68.5)
Sex
  Men 24 (77%)
  Women 7 (23%)
ECOG performance status 0–1 31 (100%)
HER2 status by IHC and FISH
  IHC 3+ 25 (80%)
  IHC 2+ 6 (20 %)
  FISH + 31 (100%)
Site of primary tumour
  Rectum 12 (39%)
  Colon 19 (61%)
   Proximal* 2 (10%)
   Distal† 17 (90%)
Metastatic disease in multiple sites 24 (77%)
Metastatic site
  Lung 25 (80%)
  Liver 24 (77%)
  Lymphnodes 7 (24%)
  Others sites 13 (42%)
Number of previous lines of therapy 3 (3–5)
Patients with >4 previous lines of 
therapy
15 (48%)
Previous anti- angiogenesis treatment 26 (83%)
Previous therapy with panitumumab or 
cetuximab
27 (87%)
Data are n (%) or median (IQR).
*Located in caecum, ascending colon, liver flexure and transverse 
colon.
†Located in splenic flexure, descending and sigmoid colon.
ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence 
in situ hybridisation; IHC, immunohistochemistry.
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Sensitivity to panitumumab or cetuximab was assessable 
in four cases, according to stringent criteria excluding 
responses to chemotherapy/anti- EGFR combinations,7 
and none had achieved a previous objective response.
At the time of data cut- off median follow- up was 7.7 
months (IQR 6.8 months). Partial response was achieved 
in 3 patients, for an ORR of 9.7% (95% CI: 0 to 28); 21 
patients (67.7% (95% CI: 50 to 85)) achieved disease 
stabilisation, accounting for a disease control rate of 
77.4%. Median PFS was 4.1 months (95% CI: 3.6 to 5.9) 
(online supplemental figure 1A). A higher HER2 IHC 
score (3+ vs 2+) was associated with better PFS: of the 31 
patients included, 25 patients with tumours displaying a 
3+ IHC score had a PFS of 5.7 months, while the PFS of 
patients with tumour scoring IHC 2+ was 1.9 months (HR 
0.20 (95% CI: 0.07 to 0.56), p=0.0008) (online supple-
mental figure 1B). Higher HER2 IHC score (3+ vs 2+) was 
also associated with objective response and long- lasting 
disease stabilisation ((≥4 months), p=0.03). Six patients 
remained stable for further 8 months from the time of 
data cut- off, and three of them up to 10 months later 
(figure 3).
Table 2 shows treatment- related adverse events that 
occurred in at least 1% of patients or all that were CTCAE 
grade 3 or worse. Treatment- related adverse events ≤grade 
2 were reported in 84% of cycles (N=296) while grade 3 
adverse event occurred only in two patients. No grade 4 
or 5 adverse events were reported. The most common all- 
grade adverse events were fatigue (14 (18%) patients), 
hyperbilirubinaemia (7 (9%) patients), thrombocyto-
paenia (6 (8%) patients), pruritus (6 (8%) patients), 
nausea/vomiting (6 (8%) patients) and muscular pain (6 
(8%) patients). The only grade 3 treatment adverse event 
was thrombocytopaenia occurring in two patients.
Only 2/31 patients required T- DM1 dose reduction 
with an overall dose intensity of 97.9%. For pertuzumab, 
no dose reduction was allowed as per protocol; inciden-
tally, we report one patient that was overdosed receiving 
138% of the intended pertuzumab dose, without toxicity.
DISCUSSION
The combination of pertuzumab and T- DM1 in HERA-
CLES- B resulted in a 9.7% ORR, thus unexpectedly not 
reaching the predetermined trial end point ≥30%. Never-
theless, the vast majority (77.4%) of patients achieved 
disease control. Interestingly, although with all the caveats 
of comparing a time- dependent secondary end point 
across different phase II trials, the median PFS in HERA-
CLES- B was in line with those reported in two other trials 
of dual anti- HER2 blockade in KRAS wild- type HER2+ 
mCRC: trastuzumab plus lapatinib in HERACLES- A and 
trastuzumab plus pertuzumab in MyPathway (4.1 vs 4.2 vs 
5.3 months, respectively).7 17
The antitumour effect observed, predominantly 
consisting of growth inhibition rather than shrinkage, 
is in line with observations in our preclinical models, 
in which the outcome was a durable stalling of tumour 
growth—persisting also after therapy suspension—rather 
than tumour regression. T- DM1 combines trastuzumab 
with DM1, a taxane- like cytotoxic agent that inhibits 
microtubule polymerisation and was specifically designed 
to minimise systemic toxicity through selective cytotoxic 
drug delivery to tumour cells.18 In mCRC, taxanes have 
failed to induce significant objective responses.19–21 
Present results of HERACLES- B trial are also consis-
tent with those of two multihistology basket trials for 
ERBB2 amplified cancers22 23 according to which T- DM1 
Figure 3 Dynamic of response in patients in HERACLES- B trial. Individual lines represent for each patient the percentage 
of change from treatment start (day 0) to the day of objective disease progression. Red lines are for patients with progressive 
disease (PD), blue lines for patients with stable disease (SD) and green lines for patients who achieved a partial response (PR). 
Pt number 122 053 rapidly progress after two cycle of pertuzumab and trastuzumab- emtansine and was not represented in the 
spaghetti plot.
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monotherapy in mCRC did not engender objective 
responses but did induce some prolonged (≥6 months) 
disease stabilisations.23 Good disease control in the pres-
ence of suboptimal induction of tumour shrinkage could 
also be explained by pharmacodynamic considerations. 
By using T- DM1 instead of trastuzumab, 30% less of the 
anti- HER2 antibody moiety was delivered during the 
first weeks of treatment due to the different schedule 
and the presence of the cytotoxic payload. The lower 
bioavailability of trastuzumab is likely counterweighed 
by the long- lasting therapeutic effect of T- DM1; indeed, 
the median PFS was comparable to that documented for 
patients who responded to anti- HER2 combination ther-
apies with tumour regression, and in preclinical models 
the growth inhibitory activity of T- DM1 plus pertuzumab 
was maintained for weeks after therapy discontinuation. 
Whether this durable impact is ascribable to the biolog-
ical cooperation between antibody- mediated inactivation 
of HER2 and the cytotoxic component, and how pertu-
zumab contributes to cancer cytostasis and prolonged 
PFS, remains to be established. Finally, no other major 
clinical or molecular factors seem to have negatively 
influenced the therapeutic efficacy in HERACLES- B as 
compared with HERACLES- A regimen, since patients in 
the former were less pretreated (48% of cases received 
4 lines of previous lines vs a median of 5 in HERACLES 
A) and distribution of HER2 IHC scoring was even 
more favourable (fractions of 3+/2+ were 81%/19% vs 
74%/26%).
The HERACLES- B regimen exhibited a very good 
toxicity profile, with drug- related grade 3 adverse events 
in only two patients (thrombocytopaenia) and grade 
≤2 events in 84% of cycles (N=296), mainly nausea and 
fatigue, also potentially suggesting a subefficacious 
dosage. The 9.7% ORR achieved by HERACLES- B 
regimen, lower than the 30% in HERACLES- A, should 
not dampen the interest for target- treating HER2+ 
mCRC; on the contrary, it underlines that several effective 
therapeutic options are at hand, including trastuzumab- 
based combinations with either small molecules tyrosine 
kinase inhibitors7 or monoclonal antibody, such as pertu-
zumab aimed, at different epitopes.17 24 Interestingly, 
recent data of the HER2+ mCRC arm of the Targeted 
Agent and Profiling Utilisation Registry study showed 
despite a higher ORR (25%) with the combination of 
trastuzumab and pertuzumab,25 as data of the KRAS wild- 
type cohort of the MyPathway trial, a similar PFS of 4.3 
months, once again indicating that a maintained disease 
control may be indicative of the antitumour potential of 
a HER2 therapeutic blockade. Other emerging thera-
peutic strategies include the development of more potent 
anti- HER2 agents,26 such as bispecific antibodies which 
can bind two non- overlapping epitopes on HER2 or 
engage immune mediators together with HER2 binding, 
and novel antibody- drug conjugates such as trastuzumab 
deruxtecan.27 The latter agent delivers through the HER2 
receptor a topoisomerase I inhibitor payload, and posi-
tive results have been recently reported for mCRC in the 
DESTINY CRC01 trial.27 28
In conclusion, the HERACLES- B trial did not reach 
its primary end point of ORR; however, this anti- HER2 
regimen provided remarkable rates of sustained disease 
control at the price of little toxicity. Therefore, this treat-
ment can be regarded as a viable therapeutic option for 
patients with HER2+ mCRC with low tumour burden 
disease not requiring substantial shrinkage, especially 
in the context of sequential lines of HER2- targeted 
therapy.29 30
Table 2 Adverse events
Grades 1–2 Grade 3
Laboratory
  Thrombocytopaenia 6 (8%) 2
  Hyperbilirubinaemia 7 (9%) 0
  ALT increase 2 (3%) 0
  Anaemia 2 (3%) 0
  Neutropenia 2 (3%) 0
Metabolic and nutritional
  Anorexia 4 (5%) 0
  Fatigue 14 (18%) 0
Dermatological
  Conjunctivitis 1 (1%) 0
  Dermatitis 5 (6%) 0
  Pruritus 6 (8%) 0
Gastrointestinal
  Abdominal pain 2 (3%) 0
  Diarrhoea 2 (3%) 0
  Nausea/Vomiting 6 (8%) 0
Pain
  Muscular pain 6 (8%) 0
Nervous
  Dysgeusia 3 (4%) 0
  Limbs paraesthesia 1 (1%) 0
Bleeding
  Epistaxis 3 (4%) 0
Respiratory
  Cough 2 (3%) 0
Fever
  Fever 2 (3%) 0
Cardiovascular
  Hypertension 1 (1%) 0
Data are n (%). Treatment- related adverse events are reported 
if they occurred in at least 1% of patients or were of Common 
Terminology Criteria for Adverse Events grade 3 or worse. All 
patients who received at least one dose of drug are included 
(n=31). No grade 4 or 5 adverse events occurred.
ALT, alanine aminotransferase.
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